NASDAQ:GOSS Gossamer Bio (GOSS) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free GOSS Stock Alerts $0.73 +0.01 (+1.38%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$0.71▼$0.7550-Day Range$0.67▼$1.5152-Week Range$0.45▼$1.88Volume2.60 million shsAverage Volume1.38 million shsMarket Capitalization$165.77 millionP/E RatioN/ADividend YieldN/APrice Target$7.65 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Gossamer Bio alerts: Email Address Gossamer Bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside943.9% Upside$7.65 Price TargetShort InterestBearish5.68% of Shares Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.38Based on 31 Articles This WeekInsider TradingSelling Shares$39,682 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.46) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.60 out of 5 starsMedical Sector795th out of 2,771 stocksPharmaceutical Preparations Industry335th out of 1,288 stocks 3.4 Analyst's Opinion Consensus RatingGossamer Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageGossamer Bio has only been the subject of 4 research reports in the past 90 days.Read more about Gossamer Bio's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.68% of the outstanding shares of Gossamer Bio have been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Gossamer Bio has recently increased by 15.66%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGossamer Bio has received a 76.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Gossamer Bio is -0.67. Previous Next 1.9 News and Social Media Coverage News SentimentGossamer Bio has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 31 news articles for Gossamer Bio this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for GOSS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,682.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gossamer Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Gossamer Bio are expected to decrease in the coming year, from ($0.46) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGossamer Bio has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Gossamer Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsMy system predicted the BA collapse – now it’s issuing an AI warningEven after several plane crashes and equipment malfunctions... a congressional hearing... and the worst PR firestorm in recent memory... The FTC's commission chair Lina Khan still deems Boeing (BA), "too big to fail" Click to see why a similar situation is currently brewing in the AI market... About Gossamer Bio Stock (NASDAQ:GOSS)Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Read More GOSS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GOSS Stock News HeadlinesMay 14 at 4:01 PM | businesswire.comGossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International ConferenceMay 13 at 5:41 AM | americanbankingnews.comFY2028 Earnings Forecast for Gossamer Bio, Inc. Issued By HC Wainwright (NASDAQ:GOSS)May 13 at 4:50 AM | americanbankingnews.comWedbush Weighs in on Gossamer Bio, Inc.'s Q1 2025 Earnings (NASDAQ:GOSS)May 11 at 4:11 AM | americanbankingnews.comQ3 2024 EPS Estimates for Gossamer Bio, Inc. Lifted by Leerink Partnrs (NASDAQ:GOSS)May 10, 2024 | businesswire.comGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Gossamer Bio Amidst Strategic Collaboration and Market Opportunity GrowthMay 10, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Gossamer Bio, Inc. Lifted by Analyst (NASDAQ:GOSS)May 9, 2024 | bizjournals.comCary headquarters plays crucial role in $160 million dealMay 9, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Gossamer Bio, Inc. (NASDAQ:GOSS) Lowered by AnalystMay 8, 2024 | msn.comGossamer Bio and Chiesi partner for pulmonary hypertension treatmentMay 8, 2024 | americanbankingnews.comGossamer Bio (NASDAQ:GOSS) Stock Rating Reaffirmed by HC WainwrightMay 7, 2024 | businesswire.comGossamer Bio Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | markets.businessinsider.comBuy Rating on Gossamer Bio Supported by Strategic Partnership and Market UnderestimationMay 6, 2024 | finance.yahoo.comUPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung conditionMay 6, 2024 | finance.yahoo.comGossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions WorldwideMay 6, 2024 | reuters.comGossamer Bio and Chiesi Group to collaborate for blood pressure treatmentMay 3, 2024 | businesswire.comGossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory MedicineMay 2, 2024 | msn.comWhat Ralph Waldo Emerson Knew About MoneyApril 26, 2024 | finance.yahoo.comGossamer Bio Decline Means Insider Profits Down To US$17kMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed on Gossamer Bio with Promising Seralutinib Prospects in PAH Treatment LandscapeMarch 21, 2024 | investing.comGossamer Bio EVP sells over $5,000 in company stockMarch 21, 2024 | investing.comGossamer Bio executive sells over $5,000 in company stockMarch 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR)March 16, 2024 | ca.finance.yahoo.comGOSS Apr 2024 1.500 putMarch 16, 2024 | finance.yahoo.comGOSS Apr 2024 1.000 putSee More Headlines Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/14/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GOSS CUSIPN/A CIK1728117 Webwww.gossamerbio.com Phone(858) 684-1300FaxN/AEmployees135Year FoundedN/APrice Target and Rating Average Stock Price Target$7.65 High Stock Price Target$15.00 Low Stock Price Target$1.25 Potential Upside/Downside+937.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-179,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-525.73% Return on Assets-62.70% Debt Debt-to-Equity Ratio7.37 Current Ratio7.13 Quick Ratio7.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book2.63Miscellaneous Outstanding Shares226,220,000Free Float214,908,000Market Cap$166.77 million OptionableOptionable Beta1.84 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Faheem Hasnain (Age 66)Co-Founder, CEO, President & Chairman Comp: $902.52kMr. Bryan Giraudo (Age 49)COO & CFO Comp: $690.59kDr. Richard Aranda M.D. (Age 63)Chief Medical Officer Comp: $625.24kMr. Christian Waage (Age 57)Executive Vice President of Technical Operations & Administration Comp: $583.16kMr. Jeff BoernekeGeneral Counsel & SecretaryMs. Deanna WeberSenior Vice President of Human ResourcesMr. Mario OrlandoSenior Vice President of Commercial New Product PlanningMs. Caryn L. Peterson (Age 65)Executive Vice President of Regulatory Affairs Mr. Matt CravetsSenior Vice President of BiometricsDr. Lisa Elizabeth Nolan Ph.D. (Age 62)MD & President of Gossamer Bio Ireland More ExecutivesKey CompetitorsSeres TherapeuticsNASDAQ:MCRBProQR TherapeuticsNASDAQ:PRQRCapricor TherapeuticsNASDAQ:CAPRSkye BioscienceNASDAQ:SKYEPrelude TherapeuticsNASDAQ:PRLDView All CompetitorsInsiders & InstitutionsPlatinum Investment Management Ltd.Sold 2,260,045 shares on 5/14/2024Ownership: 2.075%Vanguard Group Inc.Bought 128,150 shares on 5/10/2024Ownership: 5.200%Acadian Asset Management LLCBought 931,248 shares on 5/10/2024Ownership: 1.210%Monaco Asset Management SAMBought 276,000 shares on 5/9/2024Ownership: 0.246%SG Americas Securities LLCBought 28,520 shares on 5/7/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions GOSS Stock Analysis - Frequently Asked Questions Should I buy or sell Gossamer Bio stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GOSS shares. View GOSS analyst ratings or view top-rated stocks. What is Gossamer Bio's stock price target for 2024? 5 Wall Street analysts have issued 1 year price targets for Gossamer Bio's stock. Their GOSS share price targets range from $1.25 to $15.00. On average, they expect the company's stock price to reach $7.65 in the next twelve months. This suggests a possible upside of 943.9% from the stock's current price. View analysts price targets for GOSS or view top-rated stocks among Wall Street analysts. How have GOSS shares performed in 2024? Gossamer Bio's stock was trading at $0.9125 at the beginning of 2024. Since then, GOSS shares have decreased by 19.7% and is now trading at $0.7328. View the best growth stocks for 2024 here. When is Gossamer Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our GOSS earnings forecast. How were Gossamer Bio's earnings last quarter? Gossamer Bio, Inc. (NASDAQ:GOSS) issued its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.21) EPS for the quarter, hitting analysts' consensus estimates of ($0.21). What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Stoke Therapeutics (STOK), Precision BioSciences (DTIL) and Invitae (NVTA). When did Gossamer Bio IPO? Gossamer Bio (GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO. Who are Gossamer Bio's major shareholders? Gossamer Bio's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.20%), Platinum Investment Management Ltd. (2.08%), Acadian Asset Management LLC (1.21%), Monaco Asset Management SAM (0.25%), SG Americas Securities LLC (0.01%) and Sivia Capital Partners LLC (0.01%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Richard Aranda and Waage Christian. View institutional ownership trends. How do I buy shares of Gossamer Bio? Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GOSS) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe only AI company you should be looking atBehind the MarketsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.